The interface between pharmacoepidemiology and pharmacogenetics

被引:32
作者
Maitland-van der Zee, AH [1 ]
de Boer, A [1 ]
Leufkens, HGM [1 ]
机构
[1] Univ Utrecht, UIPS, Dept Pharmacoepidemiol & Pharmacotherapy, NL-3508 TB Utrecht, Netherlands
关键词
pharmacogenetics; polymorphism; pharmacotherapy; pharmacoepidemiology;
D O I
10.1016/S0014-2999(00)00810-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
One of the most challenging areas of research in pharmacoepidemiology is to understand why individuals respond differently to drug therapy, both in terms of beneficial and adverse effects. Pharmacogenetics focuses on the question to what extent variability in genetic make-up is responsible for these observed differences. Pharmacoepidemiologic research can contribute to pharmacogenetics by explaining the observed variability in drug response in 'real life' patient populations with known polymorphisms in their genetic profile. Genetic pharmacoepidemiologists also are interested in the distribution of polymorphisms and correlated frequencies of responders and non-responders in the general population, and in searching for unknown genetic links to variability in drug response. In the future, we will probably have fewer drugs that suit all individuals. Genetic pharmacoepidemiology is going to play a major role in the development and evaluation of the concept of 'tailor-made' pharmacotherapy. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:121 / 130
页数:10
相关论文
共 53 条
  • [1] Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
    Aithal, GP
    Day, CP
    Kesteven, PJL
    Daly, AK
    [J]. LANCET, 1999, 353 (9154) : 717 - 719
  • [2] Ambrosone CB, 1997, AM J EPIDEMIOL, V146, P912, DOI 10.1093/oxfordjournals.aje.a009217
  • [3] Nonfunctional CYP2D6 alleles and risk for neuroleptics-induced movement disorders in schizophrenic patients
    Andreassen, OA
    MacEwan, T
    Gulbrandsen, AK
    McCreadie, RG
    Steen, VM
    [J]. PSYCHOPHARMACOLOGY, 1997, 131 (02) : 174 - 179
  • [4] Pharmacogenetic prediction of clozapine response
    Arranz, MJ
    Munro, J
    Birkett, J
    Bolonna, A
    Mancama, D
    Sodhi, M
    Lesch, KP
    Meyer, JFW
    Sham, P
    Collier, DA
    Murray, RM
    Kerwin, RW
    [J]. LANCET, 2000, 355 (9215) : 1615 - 1616
  • [5] β2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma
    Aziz, I
    Hall, IP
    McFarlane, LC
    Lipworth, BJ
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1998, 101 (03) : 337 - 341
  • [6] Pharmacogenomics - it's not just pharmacogenetics
    Bailey, DS
    Bondar, A
    Furness, LM
    [J]. CURRENT OPINION IN BIOTECHNOLOGY, 1998, 9 (06) : 595 - 601
  • [7] Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals
    Benetos, A
    Cambien, F
    Gautier, S
    Ricard, S
    Safar, M
    Laurent, S
    Lacolley, P
    Poirier, O
    Topouchian, J
    Asmar, R
    [J]. HYPERTENSION, 1996, 28 (06) : 1081 - 1084
  • [8] BREWER GJ, 1967, B WORLD HEALTH ORGAN, V36, P303
  • [9] BULLOCK P, 1999, DRUG BENEFIT TRENDS, V11, P53
  • [10] Polymorphisms of the dopamine D4 receptor and response to antipsychotic drugs
    Cohen, BM
    Ennulat, DJ
    Centorrino, F
    Matthysse, S
    Konieczna, H
    Chu, HM
    Cherkerzian, S
    [J]. PSYCHOPHARMACOLOGY, 1999, 141 (01) : 6 - 10